Grau, Morgan
Walker, Paul R.
Derouazi, Madiha
Funding for this research was provided by:
Swiss Confederation Commission for Technology and Innovation (18520.1 PFLS-LS)
Article History
Received: 6 July 2017
Revised: 15 November 2017
Accepted: 22 February 2018
First Online: 5 March 2018
Compliance with ethical standards
:
: M. Derouazi is the CEO of Amal Therapeutics and has ownership interest (including patents) in Amal Therapeutics and patents related to cell penetrating peptide. P. R. Walker reports receiving joint funding by Swiss Confederation Commission for Technology and Innovation and Amal Therapeutics; has ownership interest in patents related to cell penetrating peptide and is a consultant/advisory board member for Amal Therapeutics.